Shanghai Schering-Plough Pharmaceutical To Transfer 45 Percent Stock
This article was originally published in PharmAsia News
Shanghai Schering-Plough Pharmaceutical, a joint venture 55 percent owned by Schering-Plough (China) Ltd., recently listed 45 percent of its equity-30 percent owned by Shanghai Pharmaceutical Industry Co. and 15 percent by Shanghai Pharmaceutical (Group)-on Shanghai United Assets and Equity Exchange for 66.329 million yuan (9.5 million). The two Chinese partners' pullout paves the way for Schering-Plough (China) to gain full control of Shanghai Schering-Plough Pharmaceutical; according to transfer terms, the foreign MNC has first rights to bid for the shares. Shanghai Schering-Plough Pharmaceutical has to defer to the policies of majority shareholder Schering-Plough (China) for its supplies and product export; thus any third-party deal will need the latter's blessings. (Click here for more - Chinese Language)
You may also be interested in...
BEIJING - Schering Plough's Chinese partners are selling all their stakes in the joint venture in Shanghai and Schering Plough plans to buy them out to begin wholly owned operations in China next year
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.